Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients

• DOI: 10.1007/s40620-022-01247-7
• Publication Date: 2022-01-27T06:02:43Z
• Authors: Michael Haase; Paul Lesny; Mark Anderson; Gavin Cloherty; Michael Stec; Anja Haase-Fielitz; Mathias Haarhaus; Carla Santos-Araújo; Pedro Mota Veiga; Fernando Macario
• Keywords: Tolerability; Heterologous

After the reports of severe adverse reactions to AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose vaccine were recommended a second Pfizer's BNT162b2 vaccine. In hemodialysis patients, we compared humoral immunogenicity and tolerability homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) BNT162b2/BNT162b2 (BNT/BNT) heterologous first ChAdOx1-nCoV-19 (ChAd/BNT). multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels, Nucleocapsid-protein-IgG-antibodies, assessed 6 weeks after in 137 24 immunocompetent medical personnel. COVID-19-naïve significantly higher median SARS-CoV-2-spike IgG levels found ChAd/BNT (N = 16) BNT/BNT 100) or ChAd/ChAd 10) (1744 [25th-75th percentile 276-2840] BAU/mL versus 361 120-936] BAU/mL; p 0.009; 1744 100 41-346] 0.017, respectively). Vaccinated, personnel 650 (25th-75th 217-1402) vaccinated prior COVID-19 7047 685-10,794) 11). multivariable regression analysis, (ChAd/BNT) was independently associated levels. The ChAd BNT (heterologous vaccination, ChAd/BNT) more frequent but manageable side effects BNT. Within limitations this appears induce stronger immunity than patients.